License and Collaboration Agreements - Notch Therapeutics (Details) - USD ($) |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
| Research and development | $ 30,721,000 | $ 40,156,000 | $ 62,724,000 | $ 90,356,000 | |
| Pre-Clinical Development Milestone | Notch Therapeutics, Inc. | Research Collaboration And License Agreement | |||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
| Research and development | 0 | $ 0 | 0 | $ 0 | |
| Notch Therapeutics, Inc. | |||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
| Equity investment | $ 0 | $ 0 | $ 0 | ||
| X | ||||||||||
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|